Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma
Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma
复制标题
肽酶抑制剂 15 作为胆管癌的新型血液诊断标志物
DOI：
10.1016/j.ebiom.2018.12.063
复制
发表时间：
2019-02-01
期刊：
影响因子：
11.1
通讯作者：
Qian, Yeben
中科院分区：
文献类型：
--
作者：
Jiang, Yong;Zheng, Xiaohu;Qian, Yeben
背景：我们的目的是筛选一种可以作为胆管癌（CCA）血液诊断标志物的特异性分泌蛋白。方法：从CCA和肝细胞癌（HCC）病例的肿瘤组织和匹配正常组织中的基因表达谱分析开始，我们确定肽酶抑制剂15（PI15）是CCA的潜在诊断标志物。我们展示了 CCA、HCC 和正常肝组织中的 PI15 表达水平。此外，定量酶联免疫吸附测定 (ELISA) 评估了 CCA (n = 61)、HCC (n = 72)、良性肝病 (n = 28)、慢性乙型肝炎 (CHB) 患者 (n = 45) 和健康个体 (n = 45) 的血浆 PI15 水平。 PI15的诊断价值通过受试者工作特征（ROC）曲线下面积（AUC）来评估。结果：PI15表达阳性率在CCA中为70%，在HCC中仅为9.1%；正常肝组织中未检测到 PI15。 CCA 患者血浆 PI15 水平明显较高，而在涉及 HCC、良性肝病、CHB 患者和健康个体的病例中仅观察到较低水平。手术后，CCA 患者的血浆 PI15 水平明显降低 (p = .0014)。血浆 PI15 区分 CCA 和 HCC 的 AUC 为 0.735。此外，CA19-9 (13 ng/ml) 的组合特异性为 94.44%，对 CCA 和 HCC 的敏感性为 80.39%。 解释：PI15 有希望成为预测 CCA 患者诊断和随访的新型标记物。 (C) 2018 年由 Elsevier B.V. 出版
Background: We aimed to screen a specific secretory protein that could serve as blood diagnostic marker for cholangiocarcinoma (CCA).Methods: Starting with the analysis of gene expression profiles in tumor tissues and matched normal tissues from cases with CCA and hepatocellular carcinoma (HCC), we identified peptidase inhibitor 15 (PI15) was a potential diagnostic marker for CCA. We demonstrated PI15 expression levels in CCA, HCC, and normal liver tissues. Furthermore, quantitative enzyme-linked immunosorbent assay (ELISA) assessed plasma PI15 levels in CCA (n = 61), HCC (n = 72), benign liver disease (n = 28), chronic hepatitis B (CHB) patients (n = 45), and healthy individuals (n = 45). The diagnostic value of PI15 was estimated by the area under the receiver operating characteristic (ROC) curve (AUC).Findings: The positive rate of PI15 expression was 70% in CCA and only 9.1% in HCC; PI15 was not detected in normal liver tissue. High levels of plasma PI15 were evident in CCA patients, whereas only low levels were observed in cases involving HCC, benign liver disease, CHB patients, and healthy individuals. Plasma PI15 levels in CCA patients were obviously reduced (p = .0014) after surgery. The AUC of plasma PI15 for discriminating between CCA and HCC was 0.735. Furthermore, with a specificity of 94.44%, the combination of CA19-9 (13 ng/ml) yielded a sensitivity of 80.39% for CCA and HCC.Interpretation: PI15 exhibits promise as a novel marker for predicting the diagnosis and follow-up of CCA patients. (C) 2018 Published by Elsevier B.V.